GLP-1 medications are the hottest way to lose weight, but are all versions of the drug being marketed to you safe?
A San Francisco-based weight loss startup, Mochi Health, is currently under a firestorm of scrutiny after working with pharmaceutical supplier Aqueita Pharmacy, which is in Kirkland, Washington.
Partnering with the NBC station in Seattle, Washington, NBC Bay Area’s Investigative Unit obtained public records showing whistleblowers went to state inspectors last year with a long list of patient safety complaints against Aequita in which Mochi’s CEO Myrah Ahmad was directly involved, they said.
About 800 miles north of Mochi Health’s headquarters at 333 Bush Street in San Francisco’s Financial District, Mochi worked with Aequita to create GLP-1 compounded medication – at one point shipping 20,000 prescriptions to patients a week across the U.S., inspectors said in their findings.
GLP-1 compounds are mixed by pharmacies to mimic brand name weight loss drugs. They’re not FDA approved and the federal agency says they can be risky.
Whistleblower reports, state findings
As Ahmad took to social media talking about Mochi’s growth and cheaper GLP-1 options for patients, Aequita pharmacy staff met with state inspectors in 2025 sharing ring videos from the facility.
The videos appear to show Aequita’s Head of Operations bring in unlicensed temporary workers to process prescriptions. The workers were picked up at home improvement store packing lots, according to six pharmacy...
Hear about the NRL star who dropped dead? Or the Richmond players who refused to wear an AFL rainbow armband? What about the Brownlow medallist involved in a stoush with Foreign Affairs Minister P...